These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 20649474)

  • 1. In vivo application of an RNAi strategy for the selective suppression of a mutant allele.
    Kubodera T; Yamada H; Anzai M; Ohira S; Yokota S; Hirai Y; Mochizuki H; Shimada T; Mitani T; Mizusawa H; Yokota T
    Hum Gene Ther; 2011 Jan; 22(1):27-34. PubMed ID: 20649474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allele-specific RNAi selectively silences mutant SOD1 and achieves significant therapeutic benefit in vivo.
    Xia X; Zhou H; Huang Y; Xu Z
    Neurobiol Dis; 2006 Sep; 23(3):578-86. PubMed ID: 16857362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis.
    Ding H; Schwarz DS; Keene A; Affar el B; Fenton L; Xia X; Shi Y; Zamore PD; Xu Z
    Aging Cell; 2003 Aug; 2(4):209-17. PubMed ID: 12934714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An RNAi strategy for treatment of amyotrophic lateral sclerosis caused by mutant Cu,Zn superoxide dismutase.
    Xia XG; Zhou H; Zhou S; Yu Y; Wu R; Xu Z
    J Neurochem; 2005 Jan; 92(2):362-7. PubMed ID: 15663483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model.
    Ralph GS; Radcliffe PA; Day DM; Carthy JM; Leroux MA; Lee DC; Wong LF; Bilsland LG; Greensmith L; Kingsman SM; Mitrophanous KA; Mazarakis ND; Azzouz M
    Nat Med; 2005 Apr; 11(4):429-33. PubMed ID: 15768029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [RNAi and neurological disease].
    Yokota T
    Rinsho Shinkeigaku; 2005 Nov; 45(11):973-5. PubMed ID: 16447777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transgenic small interfering RNA halts amyotrophic lateral sclerosis in a mouse model.
    Saito Y; Yokota T; Mitani T; Ito K; Anzai M; Miyagishi M; Taira K; Mizusawa H
    J Biol Chem; 2005 Dec; 280(52):42826-30. PubMed ID: 16221675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of functional small interfering RNAs targeting amyotrophic lateral sclerosis-associated mutant alleles.
    Geng CM; Ding HL
    Chin Med J (Engl); 2011 Jan; 124(1):106-10. PubMed ID: 21362317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNAi therapy: dominant disease gene gets silenced.
    Xu Z; Xia XG
    Gene Ther; 2005 Aug; 12(15):1159-60. PubMed ID: 15858609
    [No Abstract]   [Full Text] [Related]  

  • 10. Human Cu/Zn superoxide dismutase (SOD1) overexpression in mice causes mitochondrial vacuolization, axonal degeneration, and premature motoneuron death and accelerates motoneuron disease in mice expressing a familial amyotrophic lateral sclerosis mutant SOD1.
    Jaarsma D; Haasdijk ED; Grashorn JA; Hawkins R; van Duijn W; Verspaget HW; London J; Holstege JC
    Neurobiol Dis; 2000 Dec; 7(6 Pt B):623-43. PubMed ID: 11114261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS.
    Raoul C; Abbas-Terki T; Bensadoun JC; Guillot S; Haase G; Szulc J; Henderson CE; Aebischer P
    Nat Med; 2005 Apr; 11(4):423-8. PubMed ID: 15768028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inducible superoxide dismutase 1 aggregation in transgenic amyotrophic lateral sclerosis mouse fibroblasts.
    Turner BJ; Lopes EC; Cheema SS
    J Cell Biochem; 2004 Apr; 91(5):1074-84. PubMed ID: 15034941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. siRNA-based inhibition specific for mutant SOD1 with single nucleotide alternation in familial ALS, compared with ribozyme and DNA enzyme.
    Yokota T; Miyagishi M; Hino T; Matsumura R; Tasinato A; Urushitani M; Rao RV; Takahashi R; Bredesen DE; Taira K; Mizusawa H
    Biochem Biophys Res Commun; 2004 Jan; 314(1):283-91. PubMed ID: 14715277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Gene therapy of ALS with short interfering RNA].
    Yokota T
    Brain Nerve; 2007 Oct; 59(10):1187-94. PubMed ID: 17969360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Silencing strategies for therapy of SOD1-mediated ALS.
    van Zundert B; Brown RH
    Neurosci Lett; 2017 Jan; 636():32-39. PubMed ID: 27507699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Over-expression of Hsp27 does not influence disease in the mutant SOD1(G93A) mouse model of amyotrophic lateral sclerosis.
    Krishnan J; Vannuvel K; Andries M; Waelkens E; Robberecht W; Van Den Bosch L
    J Neurochem; 2008 Sep; 106(5):2170-83. PubMed ID: 18624915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New RNAi strategy for selective suppression of a mutant allele in polyglutamine disease.
    Kubodera T; Yokota T; Ishikawa K; Mizusawa H
    Oligonucleotides; 2005 Dec; 15(4):298-302. PubMed ID: 16396623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An enhanced U6 promoter for synthesis of short hairpin RNA.
    Xia XG; Zhou H; Ding H; Affar el B; Shi Y; Xu Z
    Nucleic Acids Res; 2003 Sep; 31(17):e100. PubMed ID: 12930974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TDP-43 physically interacts with amyotrophic lateral sclerosis-linked mutant CuZn superoxide dismutase.
    Higashi S; Tsuchiya Y; Araki T; Wada K; Kabuta T
    Neurochem Int; 2010 Dec; 57(8):906-13. PubMed ID: 20933032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Gene therapy of ALS with RNA interference].
    Yokota T
    Rinsho Shinkeigaku; 2009 Nov; 49(11):821-3. PubMed ID: 20030220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.